Susceptibility testing practices for Streptococcus pneumoniae: results of a proficiency testing survey of clinical laboratories

Diagnostic Microbiology and Infectious Disease

Volumn 55, Issue 3, 2006, Pages 225-230

  Edson, Daniel C ^a   Glick, Teri ^a   Massey, Laura D ^a  

^a American Proficiency Institute   (United States)

Author keywords

Antimicrobial susceptibility testing; Proficiency testing; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFACLOR; CEFALOTIN; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; OFLOXACIN; PENICILLIN G; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL LABORATORY; CONTROLLED STUDY; DIFFUSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

BACTERIOLOGICAL TECHNIQUES; BENCHMARKING; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; STREPTOCOCCUS PNEUMONIAE;

EID: 33747011158     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.01.010     Document Type: Article

References (20)

1. [CDC] Centers for Disease Control and Prevention. Assessment of susceptibility testing practices for Streptococcus pneumoniae-United States, February 2000. MMWR 51 (2002) 392-394
2. Doern G.V., and Brown S.D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 48 (2004) 56-65
3. Doern G.V., Brueggermann A.H., Pfaller M.A., and Jones R.N. Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program. Arch Pathol Lab Med 123 (1999) 285-289
4. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemother 50 Suppl 1 (2004) 3-10
5. Gordon K.A., Biedenbach D.J., and Jones R.N. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 46 (2003) 285-289
6. Heffernan R., Henning K., Labowitz A., Hjelte A., and Layton M. Laboratory survey of drug-resistant Streptococcus pneumoniae in New York City, 1993-1995. Emerg Infect Dis 4 1 (1998) 113-116
7. Hoban D.J., Waites K., and Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 45 (2003) 251-259
8. Jacobs M.R., Bajaksouzian S., Windau A., Good C.E., Lin G., Pankuch G.A., and Appelbaum P.C. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2003 U.S. surveillance study. Clin Lab Med 24 (2004) 503-530
9. Jones R.N. Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of American Pathologists Microbiology Surveys Program (2000). Arch Pathol Lab Med 125 (2001) 1285-1289
10. Jones R.N., Biedenbach D.J., and Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2003): report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 46 (2003) 77-80
11. Jones R.N., and Edson D.C. Special topics in antimicrobial susceptibility testing: test accuracy against methicillin-resistant Staphylococcus aureus, pneumococci, and the sensitivity to beta-lactamase methods. Am J Clin Pathol 80 Suppl (1983) 609-614
12. Jones R.N., Edson D.C., and The CAP Microbiology Resource Committee. The ability of participant laboratories to detect penicillin-resistant pneumococci. Am J Clin Pathol 78 Suppl (1982) 659-663
13. Kiehlbauch J.A., Hannett G.E., Salfinger M., Archinal W., Monserrat C., and Carlyn C. Use of the National Committee for Clinical Laboratory Standards Guidelines for Disk Diffusion Susceptibility Testing in New York State Laboratories. J Clin Microbiol 38 (2000) 3341-3347
14. Master R.N., Draghi D.C., Jones M.E., Thornsberry C., Sahm D.F., and Karlowsky J.A. Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2003 and 2003. Ann Clin Microbiol Antimicrob 3 (2004) 1. http://www.ann-clinmicrob.com/content/3/1/1 [Available from:http://www.ann-clinmicrob.com/content/3/1/1. Accessed 20 October 2005, serial online]
15. National Committee for Clinical Laboratory Standards [NCCLS]. Disk Diffusion Supplemental Tables. M100-S13 (M2) (2003), NCCLS, Wayne (Pa)
16. National Committee for Clinical Laboratory Standards [NCCLS]. MIC Testing Supplemental Tables. M100-S13 (M7) (2003), NCCLS, Wayne (Pa)
17. Stevenson K.B., Samore M., Barbera J., Moore J.W., Hannah E., Houch P., Tenover F.C., and Gerberding J.L. Detection of antimicrobial resistance by small rural hospital microbiology laboratories: comparison of survey responses with current NCCLS laboratory standards. Diagn Microbiol Infect Dis 47 (2003) 303-311
18. Steward C.D., Wallace D., Hubert S.K., Lawton R., Fridken S.K., Gaynes R.P., McGowan Jr. J.E., and Tenover F.C. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagn Microbiol Infect Dis 38 (2000) 59-67
19. Waterer G.W., Buckingham S.C., Kessler L.A., Quasney M.W., and Wunderink R.G. Decreasing β-lactam resistance in pneumococci from the Memphis region. Chest 124 (2003) 519-525
20. Whitney C.G., Farley M.M., Hadler J., and and the Active Bacterial Core Surveillance of the Emerging Infections Program Network group. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746